1. Home
  2. UPBD vs SPRY Comparison

UPBD vs SPRY Comparison

Compare UPBD & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UPBD
  • SPRY
  • Stock Information
  • Founded
  • UPBD 1986
  • SPRY 2015
  • Country
  • UPBD United States
  • SPRY United States
  • Employees
  • UPBD N/A
  • SPRY N/A
  • Industry
  • UPBD Diversified Commercial Services
  • SPRY Biotechnology: Pharmaceutical Preparations
  • Sector
  • UPBD Consumer Discretionary
  • SPRY Health Care
  • Exchange
  • UPBD Nasdaq
  • SPRY Nasdaq
  • Market Cap
  • UPBD 1.7B
  • SPRY 1.4B
  • IPO Year
  • UPBD 1995
  • SPRY N/A
  • Fundamental
  • Price
  • UPBD $32.99
  • SPRY $13.38
  • Analyst Decision
  • UPBD Buy
  • SPRY Strong Buy
  • Analyst Count
  • UPBD 6
  • SPRY 4
  • Target Price
  • UPBD $39.17
  • SPRY $24.00
  • AVG Volume (30 Days)
  • UPBD 427.5K
  • SPRY 1.3M
  • Earning Date
  • UPBD 10-31-2024
  • SPRY 11-13-2024
  • Dividend Yield
  • UPBD 4.47%
  • SPRY N/A
  • EPS Growth
  • UPBD 833.06
  • SPRY N/A
  • EPS
  • UPBD 1.49
  • SPRY N/A
  • Revenue
  • UPBD $4,259,426,999.00
  • SPRY $2,568,000.00
  • Revenue This Year
  • UPBD $9.86
  • SPRY $21,686.67
  • Revenue Next Year
  • UPBD $4.13
  • SPRY $956.61
  • P/E Ratio
  • UPBD $21.53
  • SPRY N/A
  • Revenue Growth
  • UPBD 7.43
  • SPRY 8460.00
  • 52 Week Low
  • UPBD $26.50
  • SPRY $4.65
  • 52 Week High
  • UPBD $38.72
  • SPRY $18.51
  • Technical
  • Relative Strength Index (RSI)
  • UPBD 60.08
  • SPRY 38.12
  • Support Level
  • UPBD $31.63
  • SPRY $13.36
  • Resistance Level
  • UPBD $32.76
  • SPRY $18.51
  • Average True Range (ATR)
  • UPBD 1.06
  • SPRY 1.18
  • MACD
  • UPBD 0.09
  • SPRY -0.33
  • Stochastic Oscillator
  • UPBD 69.94
  • SPRY 6.73

About UPBD Upbound Group Inc.

Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has four operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Share on Social Networks: